Higher cumulative exposure to systemic antibiotic therapy was associated with an increased risk for inflammatory bowel disease, according to a recent study. It was the top story in gastroenterology last week.

Another top story was about a study that demonstrated anti-TNF alone or in combination with thiopurines for the treatment of inflammatory bowel disease (IBD) increased the risk for lymphoma.

Read these and more top stories in gastroenterology below:

Number of antibiotic dispensations potentially linked with IBD development

Higher cumulative exposure to systemic antibiotic therapy may be associated with higher risk for the development of IBD, according to research published in Lancet Gastroenterology & Hepatology. Read more.

Anti-TNF, thiopurine combination increase lymphoma risk in IBD

Patients with IBD treated with anti-TNF either as a monotherapy or in combination with thiopurines are at increased risk for lymphoma, according to study results. Read more.

‘Food is your medicine’: Advocating for nutrition policies

Most people face incredible challenges in switching to a healthy diet. How can scientists and physicians champion the importance of fruits and vegetables and healthy eating if patients can’t pay the price or can’t find quality food in the stores nearby? Read more.

Recent reports on NASH

Investigators have recently published ample data from several nonalcoholic steatohepatitis studies. Healio presents current reports on those data and other new developments in the treatment of NASH and other liver diseases. Read more.

Histo-endoscopic mucosal healing linked with lower UC activity after induction of Stelara

Achievement of histo-endoscopic mucosal healing after induction therapy of Stelara (ustekinumab, Janssen) in patients with ulcerative colitis correlated with lower disease activity at the end of maintenance therapy compared with histologic or endoscopic improvement alone, according to results published in Gastroenterology. Read more.